Table 4. Predictors of non-responders after intravitreal aflibercept therapy for treatment-naive patients.
| BCVA |
Fundus finding |
|||||
|---|---|---|---|---|---|---|
| p value | OR | 95%CI | p value | OR | 95%CI | |
| BCVA | 0.514 | 0.355 | 0.016–7.974 | 0.806 | 1.000 | 1.000–1.000 |
| CCT | 0.756 | 1.003 | 0.985–1.021 | 0.604 | 1.003 | 0.990–1.017 |
| AMD type | ||||||
| Typical AMD | 0.841 | 1.261 | 0.130–12.22 | 0.483 | 0.515 | 0.081–3.283 |
| PCV | 0.424 | 0.359 | 0.029–4.411 | 0.306 | 2.675 | 0.406–17.64 |
| Type 1 CNV | 0.439 | 1.551 | 0.180–13.34 | 0.991 | 1.010 | 0.174–5.849 |
| Fundus findings | ||||||
| serous PED (>2DD) | 0.021* | 21.873 | 1.597–297.1 | 0.006** | 29.98 | 2.599–345.8 |
| fibrovascular PED (>3DD) | –† | –† | –† | –† | –† | –† |
| subretinal fluid | 0.780 | 0.706 | 0.061–8.178 | 0.088 | 0.240 | 0.046–1.239 |
| macular edema | 0.258 | 3.713 | 0.382–36.12 | 0.556 | 0.507 | 0.053–4.869 |
| retinal hemorrhage | 0.867 | 1.225 | 0.114–13.21 | 0.258 | 0.329 | 0.048–2.255 |
Multivariable logistic regression analyses adjusted for age, gender, CRT, and GLD at the time of initial IVA. Serous PED > 2 DD and fibrovascular PED > 3 DD were included. *p < 0.05, **p < 0.01.
†Unanalyzable because all subjects were responders.
BCVA, best corrected visual acuity; CCT, central choroidal thickness; AMD, age-related macular degeneration; PCV, polypoidal choroidal vasculopathy; CNV, choroidal neovascularization; PED, pigment epithelial detachment; CRT, central retinal thickness; GLD, greatest linear dimension.